Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 13 results
-
Feb 20, 2019With Official Launch and First Implant, Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication
DUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT) today announced both the U.S. launch of Deep Brain Stimulation (DBS) for medically-refractory epilepsy and the first commercially implanted...
-
Jun 13, 2018FDA Approved, DBS Clinician Programmer Optimizes the Programming Experience By Addressing Day-to-Day Clinical Management Challenges
DUBLIN - June 13, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) recently approved its state-of-the art...
-
May 1, 2018Medtronic Receives FDA Approval for Deep Brain Stimulation Therapy for Medically Refractory Epilepsy7-Year Data from the SANTE Trial Showed Median Seizure Frequency Reduction of 75 percent in Patients with Drug-Resistant Epilepsy with Partial-Onset Seizures Receiving DBS Therapy.
DUBLIN - May 1, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval for Medtronic'